Oral cavity cancer in two young patients with ulcerative colitis, a case report

Abstract

Patients with Inflammatory Bowel Disease (IBD) are at increased risk of developing malignancies. IBD patients with oral cavity cancer may have reduced survival compared with the general population. This article describes two IBD patients, non-smokers, on long-term use of mesalazine with the development of oral cavity cancer. In IBD the clinician should be aware of possible head and neck malignancies and in case of doubt a biopsy should be performed, even in the absence of standard risk factors.

Keywords:

• Inflammatory bowel diseases
• ulcerative colitis
• immunosuppressants
• oral cavity
• head and neck cancer

Conflicts of interest

The authors declare no conflict of interest.

Informed consent statement

Written informed consent was obtained from all subjects involved in the study.

Institutional review board statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and ethical review and approval was waived for this study based on the design of the study, and according to the national guidelines.

Data availability statement

Data available on request from the authors.